Profitability Ratios
| Ratio |
Value |
| GP Margin |
93.3% |
| EBIT Margin |
43.9% |
| EBITDA Margin |
44.7% |
| Operating Margin |
42.6% |
| Pretax Margin |
41.4% |
| Cont. Ops Margin |
124.7% |
| Net Margin |
124.7% |
| Bottom Line Margin |
124.7% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.42 |
| Quick Ratio |
2.30 |
| Solvency Ratio |
3.025 |
| Cash Ratio |
0.41 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.00 |
| Forward PEG |
0.00 |
| Price/Book |
1.97 |
| Price/Sales |
2.62 |
| Price/FCF |
10.18 |
| Price/Op Cash Flow |
10.18 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.1038 |
| Debt/Equity |
0.1362 |
| Debt/Capital |
0.1198 |
| Long-Term Debt/Capital |
0.0552 |
| Financial Leverage |
1.31 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
2.77 |
| Operating Cash Flow Ratio |
0.762 |
| Operating Cash Flow/Sales |
25.7% |
| Free Cash Flow/Operating Cash Flow |
100.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
9.98 |
| Interest Coverage |
17.1402 |
| Short-Term Operating Cash Flow Coverage |
2.49 |
| Operating Cash Flow Coverage |
1.42 |
| Capital Expenditure Coverage |
0.00 |
| Dividend + Capital Expenditure Coverage |
0.00 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
16.36 |
| EPS |
20.405 |
| Debt/Share |
3.3704 |
| Cash/Share |
8.61 |
| Book Value/Share |
21.76 |
| Tangible BV/Share |
20.39 |
| Equity/Share |
21.76 |
| Operating Cash Flow/Share |
4.206 |
| Capital Expenditure/Share |
0.000 |
| FCF/Share |
4.206 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
3.013 |
| Earnings Before Tax/EBIT |
0.971 |
| Price/Fair Value |
1.97 |
| Debt/Market Cap |
0.0692 |
| Effective Tax Rate |
-201.3% |
| Enterprise Value Multiple |
5.95 |
RIGL - Rigel Pharmaceuticals, Inc.